<ENAMEX TYPE="LOCATION">Lyphomed Inc Rosemont Ill</ENAMEX> and <ENAMEX TYPE="LOCATION">Medco Research Inc Los Angeles</ENAMEX> said the Food and <ENAMEX TYPE="ORGANIZATION">Drug Administration</ENAMEX> granted full marketing approval for a new drug for the treatment of a condition in which the heart beats between 150 and 200 beats a minute The condition known as paroxysmal supraventricular tachycardia leads to dizziness and fainting The typical healthy heart beats 70 times a minute The drug called adenocard returns the heart to a normal rhythm within seconds according to <ENAMEX TYPE="ORGANIZATION">Lyphomed Medco Research</ENAMEX> developed the drug and licensed it to <ENAMEX TYPE="ORGANIZATION">Lyphomed</ENAMEX> for sale in the <ENAMEX TYPE="ORGANIZATION">U S</ENAMEX> and <ENAMEX TYPE='untagged'>Canada</ENAMEX>